GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.

Have any questions? Please email us at ecoliwiki@gmail.com


Jump to: navigation, search


You don't have sufficient rights on this wiki to edit tables. Perhaps you need to log in. Changes you make in the Table editor will not be saved back to the wiki

See Help for Help on this wiki. See the documentation for how to use the table editor


Luchtefeld, M, Bandlow, N, Tietge, UJ, Grote, K, Pfeilschifter, J, Kaszkin, M, Beck, S, Drexler, H and Schieffer, B (2007) Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation. Atherosclerosis 194:62-70


Accumulation and modification of low density lipoproteins (LDL) within the vessel wall represent key events in atherogenesis. Secretory phospholipase A2 type IIA (sPLA2-IIA) modulates the enzymatic process of LDL-modification and was recently identified as an independent predictor of coronary events in patients with coronary artery disease (CAD). Angiotensin II (ANG II) type 1 (AT1)-receptor blockade reduces LDL-modification and atherosclerotic plaque formation in rodent and primate models of atherosclerosis. Therefore, we assessed whether ANG II via its AT1-receptor enhances sPLA2-IIA-dependent lipid peroxidation in vitro and in patients with CAD. Stimulation of rat aortic smooth muscle cells with ANG II (10(-7) mol/L) enhanced sPLA2-IIA protein expression, activity as well as LDL-peroxidation, determined by western blot, activity assay and malondialdehyde (MDA)-assay and diene formation, respectively, and were blunted by AT1-receptor blockade (Losartan, 10(-5) mol/L). In addition, ANG II-induced sPLA2 activity and LDL-peroxidation were abolished by the sPLA2-IIa activity inhibitor LY311727 (10(-5) mol/L). To evaluate a potential clinical implication, patients (n=18) with angiographically documented CAD were treated with the AT1-receptor blocker Irbesartan (IRB; 300 mg/d) for 12 weeks. Blood samples were obtained from patients pre- and post-treatment and from healthy volunteers. SPLA2-IIA serum level and activity, circulating antibodies against oxidized LDL (oxLDL), oxLDL and MDA were determined in patients and found to be significantly increased compared to healthy volunteers. IRB therapy reduced these markers of inflammation, whereas total cholesterol, HDL- and LDL-fractions remained unchanged. ANG II may elicit pro-atherosclerotic effects via type IIA sPLA2-dependent LDL-modifications. Chronical AT1-receptor blockade reduces sPLA2-IIA level and activity and subsequently lipid peroxidation. Theses findings represent a novel anti-atherosclerotic mechanism and imply that AT1-receptor blockade elicits anti-atherosclerotic potencies even in the absence of plasma cholesterol reduction.


PubMed Online version:10.1016/j.atherosclerosis.2006.09.024


Angiotensin II Type 1 Receptor Blockers/administration & dosage; Animals; Aorta/cytology; Biphenyl Compounds/administration & dosage; Cells, Cultured; Coronary Artery Disease/drug therapy; Coronary Artery Disease/metabolism; Coronary Artery Disease/pathology; Enzyme Activation/drug effects; Enzyme Activation/physiology; Enzyme Inhibitors/pharmacology; Female; Group II Phospholipases A2/antagonists & inhibitors; Group II Phospholipases A2/blood; Group II Phospholipases A2/metabolism; Humans; Hypertension/drug therapy; Hypertension/metabolism; Hypertension/pathology; Indoles/pharmacology; Lipid Peroxidation/drug effects; Lipid Peroxidation/physiology; Lipoproteins, LDL/metabolism; Losartan/pharmacology; Male; Muscle, Smooth, Vascular/cytology; Myocytes, Smooth Muscle/cytology; Myocytes, Smooth Muscle/drug effects; Myocytes, Smooth Muscle/enzymology; RNA, Messenger/metabolism; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1/genetics; Receptor, Angiotensin, Type 1/metabolism; Tetrazoles/administration & dosage